Table 2 Relationship of “emicizumab plus rFVIIa” and “emicizumab plus aPCC” targets and pathophysiological motives calculated by artificial neural networks.

From: Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Pathophysiological processes (motives)

Emi + rFVIIa

ANN category (ANN score)

Emi + aPCC

ANN category (ANN score)

TMA

 +++ (94.42%)

 +++ (91.96%)

Hyperhomocysteinemia

 + (16.67%)

 + (10.21%)

Increased coagulation

 +++ (85.2%)

 +++ (77.52%)

Increased complement activation

 + (5.09%)

 ++ (50.1%)

Increased platelet activation

 + (14.36%)

 + (37.33%)

  1. The percentage values correspond to the ANN score. Categories: High (+++) corresponds to p-value < 0.05 (ANN score [100,77]); Medium (++) corresponds to p-value < 0.25 (ANN score (77,38]); Low (+) correspond to p-value > 0.25 (ANN score < 38).
  2. ANN artificial neural networks, aPCC activated prothrombin complex concentrate, Emi emicizumab, rFVIIa recombinant activated factor VII, TMA thrombotic microangiopathy.
Back to article page